[关键词]
[摘要]
脓毒症是针对感染的宿主反应失调引起的致命性器官功能障碍。该病患者院内病死率高达10%以上,导致临床治疗费用高,医疗资源消耗大,已经对人类健康造成了巨大威胁。抗生素、抗病毒药物、血管活性药等均用于脓毒症传统治疗,但尚未有足够的针对脓毒症发病机制的特异性药物投入临床实践。如何及时纠正脓毒症发生发展过程中的全身性炎症反应、凝血功能障碍和免疫功能紊乱,尽早恢复机体促炎-抗炎动态平衡,有效改善患者预后,也成为了脓毒症治疗药物研究首先要考虑的问题。根据针对脓毒症发病阶段和治疗目的的不同,脓毒症特异性治疗药物主要分为针对失控炎症反应的药物、针对凝血功能障碍的药物、针对免疫功能抑制的药物和整体调节的现代中药4大类。主要对上述脓毒症特异性治疗药物进行综述。
[Key word]
[Abstract]
Sepsis has been defined as life-threatening organ dysfunction caused by dysregulated host response to infection, associated with an in-hospital mortality in excess of 10% and leading to high treatment cost and medical resources consumption, has become a huge threat to human health. Antibiotics, antiviral drugs, vasoactive agents, etc. have been used in the traditional therapy of sepsis, but there are also not enough specific therapeutic drugs for clinical practice. How to rectify systemic inflammatory response, coagulation disorders, and immune dysfunction, contributing to return to pro-and anti-inflammatory homeostasis, and improve patient outcomes, is the key problem in anti-sepsis drug development. According to the differences of disease stage and treatment purposes, specific therapeutic drugs for the treatment of sepsis are divided into drugs aiming at uncontrolled inflammatory response, coagulation disorders, immune function inhibition, and modern Chinese medicine. Research progress on those specific therapeutic drugs for the treatment of sepsis are reviewed in this paper.
[中图分类号]
[基金项目]
天津市科技小巨人领军企业培育重大项目(14ZXLJSY00230)